Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

NCT03925532 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Osteopenia
Osteoporosis

Interventions

BIOLOGICAL: Denosumab

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]